Likelihood that a woman with screen-detected breast cancer has had her "life saved" by that screening.
نویسندگان
چکیده
BACKGROUND Perhaps the most persuasive messages promoting screening mammography come from women who argue that the test "saved my life." Because other possibilities exist, we sought to determine how often lives were actually saved by mammography screening. METHODS We created a simple method to estimate the probability that a woman with screen-detected breast cancer has had her life saved because of screening. We used DevCan, the National Cancer Institute's software for analyzing Surveillance Epidemiology and End Results (SEER) data, to estimate the 10-year risk of diagnosis and the 20-year risk of death--a time horizon long enough to capture the downstream benefits of screening. Using a range of estimates on the ability of screening mammography to reduce breast cancer mortality (relative risk reduction [RRR], 5%-25%), we estimated the risk of dying from breast cancer in the presence and absence of mammography in women of various ages (ages 40, 50, 60, and 70 years). RESULTS We found that for a 50-year-old woman, the estimated risk of having a screen-detected breast cancer in the next 10 years is 1910 per 100,000. Her observed 20-year risk of breast cancer death is 990 per 100,000. Assuming that mammography has already reduced this risk by 20%, the risk of death in the absence of screening would be 1240 per 100,000, which suggests that the mortality benefit accrued to 250 per 100,000. Thus, the probability that a woman with screen-detected breast cancer avoids a breast cancer death because of mammography is 13% (250/1910). This number falls to 3% if screening mammography reduces breast cancer mortality by 5%. Similar analyses of women of different ages all yield probability estimates below 25%. CONCLUSIONS Most women with screen-detected breast cancer have not had their life saved by screening. They are instead either diagnosed early (with no effect on their mortality) or overdiagnosed.
منابع مشابه
Breast cancer screening by mammography in Norway. Is it cost-effective?
BACKGROUND Mammography screening is a promising method for improving prognosis in breast cancer. PATIENTS AND METHODS In this economic analysis, data from the Norwegian Mammography Project (NMP), the National Health Administration (NMA) and the Norwegian Medical Association (NMA) were employed in a model for cost-effectiveness analysis. According to the annual report of the NMP for 1996, 60,1...
متن کاملSerendipitous Detection of Asymptomatic Lesions in International Travellers
The recent case of a 41-year-old British tourist, whose breast cancer was first suggested by a visit to a popular tourist attraction in Scotland, prompted us to consider how travel may serendipitously yield unforeseen diagnoses. The woman and her family were entertained in the thermal imaging camera room of the Camera Obscura and World of Illusions exhibit in Edinburgh when she noticed that her...
متن کاملRe: Pan-Canadian study of mammography screening and mortality from breast cancer.
We were struck by the large reduction in breast cancer mortality reported by Coldman et al. in association with participation in Canadian mammography screening programs (1), in particular with the consistency in the sizes of the observed reductions across all provinces and across all age groups. Overall, they reported a 40% reduction in breast cancer mortality associated with ever participating...
متن کاملMutation Screening of BRCA Genes in 10 Iranian Males with Breast Cancer
Male breast cancer is a rare disease with an increasing trend. Due to limited information especially about the genetic basis of the disease in Iran and the lower age of its onset, the disease requires more attention. The aim of this study was to screen the male patients with breast cancer for BRCA mutations as well as tissue markers of estrogen receptor (ER), progesterone receptor (PR), human e...
متن کاملBreast metastasis from the pancreatic neuroendocrine tumor origin detected by 99mTc-Octreotate scan
A 50 years old woman with history of pancreatic neuroendocrine tumor diagnosed 2 years ago, which has not been surgically removed,was referred to our department for a 99mTc-Octreotate in order to evaluate the somatostatin receptor status. She was treated with regular sandostatin injections and chemotherapy. Her CT scan which was previously performed confirmed lung, adrenal and hepati...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Archives of internal medicine
دوره 171 22 شماره
صفحات -
تاریخ انتشار 2011